Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can less be more? testing transfusion limits in ECMO

NCT ID NCT06560164

Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial asks whether a restrictive red blood cell transfusion strategy is as safe as a liberal one for adults on ECMO, a life-support machine for heart or lung failure. Patients will be randomly assigned to receive transfusions only when their hemoglobin drops to 7.0 g/dL (restrictive) or 9.0 g/dL (liberal). The main goal is to compare 90-day survival rates between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Red blood cell transfusion
What this could lead to
If a restrictive transfusion strategy proves non-inferior, it could reduce transfusion-related risks and costs for ECMO patients, potentially improving outcomes.
What could go wrong
This is a non-inferiority trial, so it may show that restrictive transfusions are not as safe. Transfusions themselves carry risks, and the trial's results may not apply to all ECMO patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 526 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is aged 18 years or older; * Is receiving ECMO; * (Deferred) informed consent. Exclusion Criteria: * Not expected to survive for 24 hours when assessed; * Inability to receive blood products; * (Known) decline to blood transfusions (e.g., Jehovah's Witnesses); * Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+); * Received ECMO over 48h before screening for eligibility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia ECMO Extracorporeal membrane oxygenation Red blood cell Transfusion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC, location AMC

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • CHU Charleroi

    RECRUITING

    Charleroi, Hainaut, 6000, Belgium

  • Erasmus MC

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Hôpital Erasme

    RECRUITING

    Brussels, Brussels Capital, 1070, Belgium

  • KU Leuven, medical IC

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium

  • KU Leuven, surgical IC

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium

  • Karolinska Universtiy Hospital

    RECRUITING

    Stockholm, Stockholm County, 171 76, Sweden

  • Leids Universitair Medisch Centrum (LUMC)

    RECRUITING

    Leiden, South Holland, 2333 ZA, Netherlands

  • Maastricht Universitair Medisch Centrum+ (MUMC+)

    RECRUITING

    Maastricht, Limburg, 6229 HX, Netherlands

  • MedUni Wien

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

  • Medisch Spectrum Twente (MST)

    RECRUITING

    Enschede, Drenthe, 7512 KZ, Netherlands

  • Radboudumc

    NOT_YET_RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

  • St. Antonius Ziekenhuis

    RECRUITING

    Nieuwegein, Utrecht, 3435 CM, Netherlands

  • Universitair Medisch Centrum Groningen (UMCG)

    RECRUITING

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.